Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCOUT-CAP: Short vs Standard Course Therapy for CAP in Children
NCT02891915Phase 4Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2016
- Primary completion
- Dec 2019
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of amoxicillin, amoxicillin + clavulanate and cefdinir in community acquired pneumonia (CAP) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Desirability of Outcome Ranking at Day 8. Started Dec 2016; status: completed.
02
Drugs
amoxicillinamoxicillin + clavulanatecefdinir
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT02891915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02891915.